Abstract:INTRODUCTION AND OBJECTIVES: Sphingosine kinase 1 (SphK1) is the major source of the bioactive lipid and GPCR (G-proteincoupled receptor) agonist sphingosine 1-phosphate (S1P). Numerous studies have documented that SphK1-S1P signalling has multiple functions in tumorigenesis. The present study was conducted to investigate the expression of SphK1-S1P signalling and its prognostic significance in renal cell carcinoma (RCC). Meanwhile, we set out to SphK1 as a novel molecular target in RCC and examine its role in tumor cell growth and sunitinib resistance in vitro and in vivo. METHODS: In this study, SphK1 expression levels as well as clinicopathological significance were evaluated in RCC cell lines and primary RCC clinical specimens by immunohistochemistry, immunofluorescence assay, qRT-PCR and western blot. We assessed the levels of S1P and Sph in tumor tissues by HPLC analysis and in the plasma of RCC patients and healthy controls by LC-MS/MS analysis. In vitro and in vivo knockdown or overexpression of SphK1 in RCC cell lines was used to determine its effecton tumor growth, cellular proliferation, colony formation, migration, invasion, and apoptosis. We conducted a phosphoprotein antibody array to identify ectopic phosphorylated proteins induced in 786-O cells with/without SphK1 expression vector. In addition,we further evaluated the effect of SphK1 antagonist fingolimod (FTY720) in RCC in vitro and in vivo, as a single agent or in combination with sunitinib, and attempted to explore its anticarcinogenic mechanisms. RESULTS: We identify upregulation of SphK1 significantly associated with poor prognosis of RCC patients, which contributing to renal proliferation, colony formation, migration and survival. Suppression of SphK1 activity either by shRNA or pharmacologic inhibitior FTY720 suppresses cell growth in vitro and in vivo. A comprehensive phosphoprotein antibody array reveals that SphK1 overexpression promoted RCC progression by regulating the Akt/mTOR pathway. SphK1 could act as a canonical regulator of hypoxia-inducible HIF-1&agr; and HIF-2&agr; in RCC cells. Moreover, stem-like phenotype due to sunitinib administration via oncogenic activation of SphK1 could be ameliorated by SphK1 shRNA and FTY720. FTY720 administration enhanced tumor growth inhibition effect of sunitinib treatment on RCC cells in vitro and in vivo. CONCLUSIONS: Our results unraveled that increased SphK1 kinase activation defines an important mechanism for maintaining stemlike phenotype and sunitinib resistance, therefore contributes to tumour development and represents therapeutic targets for RCC. Source of Funding: none

The significance of SMARCB1 in the pathogenesis of renal cell carcinoma with rhabdoid features

RCC1 functions as a tumor facilitator in clear cell renal cell carcinoma by dysregulating cell cycle, apoptosis, and EZH2 stability

SMARCC1 Expression is Positively Correlated with Pathological Grade and Good Prognosis in Renal Cell Carcinoma

An Integrated Genomic Analysis of Papillary Renal Cell Carcinoma Type 1 Uncovers the Role of Focal Adhesion and Extracellular Matrix Pathways

Coexistent Loss of Ini1 and Brg1 Expression in A Rhabdoid Renal Cell Carcinoma (rcc): Implications for A Possible Role of Swi/Snf Complex in the Pathogenesis of Rcc

RHBDD1 promotes proliferation, migration, invasion and EMT in renal cell carcinoma via the EGFR/AKT signaling pathway

Tertiary Lymphoid Structures Potentially Promote Immune Checkpoint Inhibitor Response in SMARCB1-deficient Medullary Renal Cell Carcinoma

MCP-1/MCPIP-1 Signaling Modulates the Effects of IL-1β in Renal Cell Carcinoma through ER Stress-Mediated Apoptosis

RRM2 Regulates Sensitivity to Sunitinib and PD‐1 Blockade in Renal Cancer by Stabilizing ANXA1 and Activating the AKT Pathway

PBRM1 Regulates Proliferation and the Cell Cycle in Renal Cell Carcinoma Through a Chemokine/chemokine Receptor Interaction Pathway

Inactivation of BRM/SMARCA2 Sensitizes Clear Cell Renal Cell Carcinoma to Histone Deacetylase Complex Inhibitors

The E3 ligase RBCK1 reduces the sensitivity of ccRCC to sunitinib through the ANKRD35-MITD1-ANXA1 axis

PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma

RCAN1.4 Acts As a Suppressor of Cancer Progression and Sunitinib Resistance in Clear Cell Renal Cell Carcinoma

TIMP1 Shapes an Immunosuppressive Microenvironment by Regulating Anoikis to Promote the Progression of Clear Cell Renal Cell Carcinoma.

EIF3D Silencing Suppresses Renal Cell Carcinoma Tumorigenesis Via Inducing G2/M Arrest Through Downregulation of Cyclin B1/CDK1 Signaling.

RIN1 Promotes Renal Cell Carcinoma Malignancy by Activating EGFR Signaling Through Rab25.

Global Chromatin Changes Resulting from Single-Gene Inactivation-The Role of SMARCB1 in Malignant Rhabdoid Tumor

MP21-17 SPHINGOSINE KINASE 1 OVEREXPRESSION CONTRIBUTES TO SUNITINIB RESISTANCE IN CLEAR CELL RENAL CELL CARCINOMA

MiR-1 Downregulation Correlates with Poor Survival in Clear Cell Renal Cell Carcinoma Where It Interferes with Cell Cycle Regulation and Metastasis.

NF-κB and EGFR participate in S1PR3-mediated human renal cell carcinomas progression